SLC5A2 and type 2 diabetes mellitus: Empirical data supports that SGLT-2 inhibitors significantly reduce the risk of hospitalization for HF treatment in type 2 diabetes patients without a history of HF [2]; furthermore, SGLT-2 inhibitors have significantly reduced the composite endpoint of cardiovascular death or hospital readmissions due to worsening HF in patients with HF [3].